<DOC>
	<DOC>NCT01560143</DOC>
	<brief_summary>If tigecycline clearance increases with body size then serum exposure values will be lower in obese class III compared to normal weight subjects because exposure changes inversely with clearance when the dose is fixed without regard to weight.</brief_summary>
	<brief_title>Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects</brief_title>
	<detailed_description>Not required</detailed_description>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Subjects fulfilling the following criteria will be eligible: 1. males and females, 18 to 50 years of age; 2. nonsmoking or lightsmoking (≤ 5 cigarettes per day) volunteers; 3. Body mass index: 18.5024.99 kg/m2 (normal weight) or ≥ 40 kg/m2 (obese class III); 4. female subjects of childbearing potential (selfreported) either surgically sterilized, using an effective method of contraception (diaphragm, cervical cap, condom) or agree to abstain from sex from time of prestudy screening, during entire study period and 1 month following the study period 1. history of significant hypersensitivity reaction to any components of Tygacil®; 2. history of significant clinical illness requiring pharmacological management; 3. history of blood donation in the past eight week period; 4. abnormal serum electrolyte or complete blood count requiring further clinical workup; 5. transaminases (AST or ALT) &gt; 2.5 x upper limit of normal; 6. subjects with stage 4 or 5 chronic kidney disease; 7. positive serum pregnancy test (if female); 8. abnormal electrocardiogram (ECG) as judged by study physician; 9. unable to tolerate venipuncture and multiple blood draws; 10. clinically significant abnormal physical examination defined as a physical finding requiring further clinical workup; 11. unable to independently provide a written informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>